FOCUSED ON AI
& NOVEL DRUG
At A2A Pharmaceuticals, our mission is to leverage proprietary computational systems, including A.I., to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.
Significant Achievements to Date
Partnership with Insilico Medicine to develop a novel therapeutics for Duchenne Muscular Dystrophy.
Won the J&J Innovation Artificial Intelligence Challenge for drug discovery.
Enter into 50/50 partnerships with
former management of Pharmacyclics to advance the leukemia program
into Phase I studies in 2019.
Raised a total of $5 million in financing.
Revenue generating pilot projects with Novartis and Proctor & Gamble to sign new drug candidates.
Seed funding through SOSV and incubation at IndieBio.
Partnership with DAEWOONG Pharmaceutical to develop oncology therapeutics.
Focus indications are in difficult to drug targets, including protein-protein interactions, in leukemia and other solid tumor cancers, as well as Muscular Dystrophy and drug-resistant bacterial infections.
Robust Development Pipeline & Partnerships
(Tumor Myeloid cells)
(Cancer & DMD)
(Gram - Bacteria)
Partnerships with Novartis and Proctor & Gamble to design drug candidates for cardiavascular and cancer targest